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Telomeres and the insulin/PI3K pathway are considered hallmarks of aging and cancer. Here,
we describe a role for PI3K/AKT in the regulation of TRF1, an essential component of the
shelterin complex. PI3K and AKT chemical inhibitors reduce TRF1 telomeric foci and lead to
increased telomeric DNA damage and fragility. We identify the PI3Kα isoform as responsible
for this TRF1 inhibition. TRF1 is phosphorylated at different residues by AKT and these
modifications regulate TRF1 protein stability and TRF1 binding to telomeric DNA in vitro and
are important for in vivo TRF1 telomere location and cell viability. Patient-derived breast
cancer PDX mouse models that effectively respond to a PI3Kα specific inhibitor, BYL719,
show decreased TRF1 levels and increased DNA damage. These findings functionally connect
two of the major pathways for cancer and aging, telomeres and the PI3K pathway, and
pinpoint PI3K and AKT as novel targets for chemical modulation of telomere protection.
DOI: 10.1038/s41467-017-01329-2 OPEN
1 Telomeres and Telomerase Group, Molecular Oncology Program, Spanish National Cancer Centre (CNIO), Melchor Fernández Almagro 3, Madrid E-28029,
Spain. 2 Experimental Therapeutics Program, Spanish National Cancer Centre (CNIO), Melchor Fernández Almagro 3, Madrid E-28029, Spain.
3 Biotechnology Program, Spanish National Cancer Centre (CNIO), Melchor Fernández Almagro 3, Madrid E-28029, Spain. 4 Experimental Therapeutics
Group, Vall d´Hebron Institute of Oncology (VHIO), Natzaret 115-117, Barcelona E-08035, Spain. Marinela Méndez-Pertuz and Paula Martínez contributed
equally to this work. Correspondence and requests for materials should be addressed to M.A.B. (email: mblasco@cnio.es)







Telomeres are nucleoprotein structures located at the endsof eukaryotic chromosomes that protect them fromdegradation and DNA repair activities, ensuring chromo-
somal stability1. One of the hallmarks of cancer is the ability of
cancer cells to maintain functional telomeres, mainly through the
activation of telomerase, the enzyme that elongates telomeres,
thus allowing for telomere maintenance and indefinite cancer cell
division2, 3. Targeting telomeres in cancer has been a goal for the
past decades. However, telomerase inhibition in cancer cells only
showed effectiveness in some myeloid tumors and has largely
failed in other tumor types4–6. This is likely due to the fact that
telomerase is not essential for cell division until telomeres reach a
critically short length, together with the fact that tumors contain
heterogeneous cell populations also with regard to telomere
length7–10. In addition, alternative mechanisms to elongate telo-
meres known as ALT can be activated in telomerase-negative
tumors4–6.
In vertebrates, telomeres are composed of tandem repeats of
the TTAGGG sequence bound by a six protein complex known as
shelterin, which encompasses TRF1, TRF2, TIN2, POT1, RAP1,
and TPP111, 12. The telomere repeat binding factor 1 (TRF1) was
the first shelterin to be discovered13 and it is one of the best
characterized. TRF1 binds to telomeric DNA as a homodimer,
thus protecting telomeres14, 15. A number of reports have shown
that binding of human TRF1 to telomeres can be regulated post-
translationally. Among these modifications, polyADP ribosyla-
tion of TRF1 is the best understood. ADP-ribosylation of human
TRF1 by tankyrase 1 releases TRF1 from telomeres promoting its
ubiquitination and proteasome-mediated degradation16–20. Other
modifications include phosphorylation by polo-like kinase 1
(PLK1), cyclin B-dependent kinase 1 (CDK1), casein kinase 2
(CK2), a member of the never in mitosis gene A (NIMA) kinase
family Nek7, and by AKT20–25. However, functional relevance of
these modifications is poorly understood. TRF1 is also regulated
at the transcriptional level by the pluripotency factor Oct4, which
binds to TRF1 promoter and it is sufficient to highly upregulate
TRF1 messenger RNA (mRNA) and protein levels during in vitro
generation of induced pluripotent stem cells (iPS cells)26. Indeed,
TRF1 has an essential role both in the induction and maintenance
of the pluripotency state26. In agreement with this, genetic
depletion of TRF1 leads to mouse lethality at the blastocyst
stage27.
In the context of differentiated tissues, genetic deletion of TRF1
in adult mice results in loss of telomere protection, increased
telomere fragility, and activation of a persistent DNA damage
response (DDR) at chromosome ends, which leads to cellular
senescence and/or apoptosis and to severe impairment of tissue
regeneration and organismal viability26, 28–31. All these effects
occur in the absence of telomere shortening, indicating that TRF1
inhibition is sufficient to induce severe telomere dysfunction in
the absence of telomere shortening. Thus, shelterins could be
potential therapeutic targets to rapidly disrupt telomeres in can-
cer cells independently of telomere length, in this manner over-
coming the limitations of telomerase inhibition. Indeed, similar to
telomerase, some shelterin components have been recently found
mutated both in familial and sporadic human tumors, such as
mutations in the TRF1-interacting protein POT132–38. Further-
more, we recently demonstrated that genetic deletion of TRF1 in
a mouse lung cancer model impairs the growth of p53-null K-
RasG12V-induced lung carcinomas and increases mouse survival
independently of telomere length39. In particular, TRF1 genetic
deletion impaired cancer growth concomitant with induction of
telomeric DNA damage, apoptosis, decreased proliferation, and
G2-arrest39. These phenotypes associated to TRF1 genetic dele-
tion were also achieved by using small molecule inhibitors of
TRF1 telomeric foci39. These TRF1 inhibitors were identified in a
phenotypic screening to disrupt TRF1 foci using a curated library
(ETP-640) representing the chemical space of our in-house
50,000 compound ETP-CNIO collection39.
The phosphatidylinositol-3-kinase (PI3K) pathway regulates a
wide range of target proteins to control cell proliferation, survival,
and cell growth40. There are three major classes of PI3K enzymes,
being class IA widely associated to cancer. Class IA PI3K are
heterodimeric lipid kinases composed of a catalytic subunit
(p110α, p110β, or p110δ; encoded by PIK3CA, PIK3CB, and
PIK3CD genes, respectively) and a regulatory subunit (p85)41.
Following extracellular mitogenic stimulation, activated
p110 subunit catalyzes the production of phosphatidylinositol-
3,4,5-triphosphate, a lipid second messenger, that in turn acti-
vates the serine/threonine protein kinase AKT/protein kinase B
(PKB) and other effectors41. A number of mutations in the PI3K/
ATK pathway have been found in human cancers42, 43, thus
targeting the PI3K pathway is a therapeutic strategy in cancer44.
Although many PI3K downstream targets are proposed to med-
iate the role of PI3K in cancer45, 46, none of them have been
linked to maintenance of chromosomal stability or to telomere
function, which are hallmarks of cancer47.
In analogy to telomeres, PI3K also has a fundamental role in
aging and longevity48, 49. In particular, PI3K is downstream of the
glucose-dependent and of IGF-1 signaling pathways and its
downregulation, as well as downregulation of its downstream
kinases mTOR and S6K is shown to extend life-span in several
organism from yeast to mice48, 50–54.
As mentioned above for TRF126, the PI3K pathway also plays
crucial role in maintenance of pluripotency and in the survival of
iPS cells (IPSCs)55, 56. Indeed, reprogramming efficiency is
enhanced by the combined chemical inhibition of a PI3K
downstream target, namely GSK3-β and a RAS downstream
target MEK/ERK57. In particular, the glycogen synthase kinase
(GSK3) is downstream of PI3K/AKT and is repressed upon PI3K-
AKT signaling58. A connection between TRF1 and the PI3K
pathway in the maintenance of the pluripotency state is unknown
to date.
In this report, we make the discovery that the TRF1 telomeric
protein is regulated by the PI3K signaling pathway. In particular,
inhibition of PI3K and of its downstream target AKT by small
molecules, as well as genetic depletion of the PIK3CA gene
encoding the p110α catalytic subunit of PI3Kα resulted in
decreased TRF1 protein levels and decreased TRF1 telomeric foci.
This in turn lead to increased telomere fragility and increased
telomere aberrations (i.e., multitelomeric signals). We further find
that AKT phosphorylates purified TRF1 in vitro, suggesting a
direct involvement of PI3K/AKT axis in the regulation of TRF1.
In this regard, we identify three AKT phosphorylation sites in
TRF1 at residues T248, T330, and S344. Overexpression of eGFP-
tagged Trf1 mutants Trf1T330A and Trf1S344A rendered sig-
nificantly lower TRF1 telomeric foci compared to cells expressing
wild-type Trf1 both in lung tumor cells and in MEFs. In addition,
while wild-type eGFP-tagged Trf1 was able to rescue proliferation
of TRF1-deficient MEFs, this was not the case for eGFP-tagged
Trf1 mutants Trf1T330A and Trf1S344A, thus demonstrating the
relevance of these AKT-dependent TRF1 modifications for cell
viability and TRF1 telomeric foci formation in vivo.
Finally, we extended these findings to the clinical setting by
using patient-derived xenograft (PDX) models. We show that
patient-derived breast cancer PDX models that responded to the
treatment with a specific PI3Kα inhibitor also show significantly
decreased TRF1 levels and increased telomeric DNA damage.
Together, these findings demonstrate a central role of the PI3K/
AKT pathway in regulation of telomere protection, thus high-
lighting components of this pathway as novel targets for
telomere-based therapies in cancer and age-related diseases.
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Results
The PI3K-AKT pathway regulates TRF1 telomeric foci. By
performing a high-throughput phenotypic screening designed to
identify compounds that disrupt the location of eGFP-tagged TRF1
to telomeres, we previously identified the hit compounds ETP-
47037 and ETP-47228 (proprietary CNIO compounds) as inhibi-
tors of eGFP-TRF1 telomeric foci fluorescence (Fig. 1a, top)39.
Here, we set to deconvolute the molecular pathways respon-
sible for inhibition of TRF1 foci by these small molecules. We
noted that both compounds belonged to a chemical series
previously identified by us as PI3K inhibitors59, 60, thus we set to
address whether the PI3K pathway was able to regulate TRF1 foci
formation. First, we confirmed that both ETP-47037 and ETP-
47228 had a potent inhibitory activity against the PI3Kα isoform,
with IC50 values of 0.99 and 2.6 nM, respectively (Fig. 1b,
“Methods” section). In addition, ETP-47037 also inhibited the
PI3Kβ, PI3Kδ, and PI3Kγ isoforms, with IC50 values of 49.2, 7.13,
and 49.1 nM, respectively (Fig. 1b). Of interest, ETP-47037 did
not inhibit significantly the PI3K downstream kinase mTOR
kinase, (IC50 of 1.7 μM), while ETP-47228 showed a moderate
mTOR kinase inhibition (IC50 of 443 nM) (Fig. 1b).
Next, to address whether PI3K activity was responsible for the
inhibition of TRF1 foci, we designed two close analogs of the
active compounds ETP-47037 and ETP-47228, ETP-51259 and
ETP-50952, respectively, with a negligible activity against PI3K
(Fig. 1a, b). These new chemical probes were prepared by
replacement of a single key oxygen atom from the morpholine
moiety by a methylene group, generating the piperidine
derivatives ETP-51259 and ETP-50952 (Fig. 1a). To assess their
PI3K cellular activity, we measured phosphorylation of residue
Ser473 in AKT (p-AKT S473), a PI3K downstream target61–63, by
western blot analysis. To this end, we used the CHA-9.3 mouse
lung cancer cell line previously generated by us39. As expected, p-
AKT S473 was strongly inhibited by our active compounds ETP-
47037 and ETP-47228, but largely unaffected by their inactive
versions (ETP-51259 and ETP-50952) (Fig. 1c). Of note, the
inhibitory activity of ETP-47037 was more prolonged than that of
ETP-47228. Thus, ETP-47037 mediated p-AKT S473 inhibition
was maintained during the 24-hour treatment while the ETP-
47228 mediated inhibition decreased 35% after 24 h as compared
to 1-h treatment but still was able to inhibit the pathway above
50% (Fig. 1c).
We also determined the effect of ETP-47037 and ETP-47228 in
the inhibition of other PI3K downstream targets, PRAS40 (T246),
and pS6 (S235/236)64, 65 (Supplementary Fig. 1). The results
clearly show that both ETP compounds constitute bona fide
inhibitors of the PI3K/AKT axis.
Next, we addressed whether the inactive PI3K/AKT com-
pounds also failed to inhibit TRF1 foci when used in in vivo
cellular assays. To this end, we treated CHA-9.3 cells with a 10
μM concentration of both the active and inactive chemical probes
for 24 h and quantified TRF1 spot intensity by immunofluores-
cence (i.e., TRF1 shows a spotted pattern in interphase nuclei
corresponding to telomeres)29 (“Methods” section). Interestingly,
cells treated with the inactive ETP-51259 and ETP-50952
compounds showed negligible inhibition of TRF1 foci, in contrast
to efficient inhibition of TRF1 foci by the active compounds ETP-
47037 and ETP-47228 (Fig. 1d), confirming that inhibition of
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Fig. 1 Chemical inhibition of TRF1 binding to telomere by PI3K inhibitors. a Structures of ETP-47037, ETP-47228, and their corresponding “inactive analogs”
ETP-51259 and ETP-50952. b PI3K/mTOR IC50 data generated internally and reported for the inhibitors used in the study. c Time course Inhibition of AKT
phosphorylation at Ser473 by ETP-47037, ETP-51259, ETP-47228, and ETP-50952 at 10 μM in CHA-9.3 cell line. d Percent inhibition of TRF1 foci by
immunofluorescence in CHA-9.3 mouse lung tumor cell line treated with 10 μM of either ETP-47037, ETP-47228, or their corresponding inactive analogs
(ETP-51259 and ETP-50952, respectively) relative to TRF1 levels with DMSO treatment. The ETP compound inhibitory activity on PI3K pathway is stated at
the bottom of the graph. Error bars represent standard deviation. N/D not determined, n number of independent experiments
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As we observed that ETP-47228 also showed some inhibition of
the PI3K/AKT downstream kinase mTOR (IC50 of 443 nM;
Fig. 1b), we set to address whether inhibition of TRF1 foci by these
compounds was mediated by mTOR. To this end, we treated cells
with a wide panel of available PI3K inhibitors, with or without
activity against mTOR (Fig. 2a–d). We selected compounds
sharing similar structural features to our hits, such as ETP-46992,
another CNIO proprietary inhibitor66 and GDC-094167, or with
quite dissimilar structures such as BKM-12068, BYL-71969, TGX-
22170, BEZ-23571, MK-220672, and GSK-212645873 (Fig. 2a). We
determined the activity of the different compounds against the
PI3Kα isoform and against mTOR by using biochemical assays for
each enzyme, and obtained IC50 values similar to those previously
reported for these compounds (Fig. 2b) (“Methods” section). In
particular, all the compounds inhibited PI3Kα at nanomolar level,
except TGX-221, which showed negligible PI3Kα inhibition
(Fig. 2c, d). Regarding mTOR inhibition, BEZ-235 and GSK-
2126458 presented potent nanomolar mTOR inhibition, whereas
GDC-0941, BKM-120 and ETP-46992, showed a micromolar
activity against mTOR (Fig. 2b). Finally, the PI3Kα selective
inhibitor BYL-719 did not inhibit mTOR (IC50 > 10 μM), and
thus was used as a good chemical probe to test the influence of
mTOR on TRF1 foci formation.
The kinase selectivity of the inhibitors used here was ensured in
order to discard potential off-targets effects contributing to the
observed TRF1 modulation. Thus, ETP-47037 and ETP-47228
were profiled against a panel of 24 kinases representing the
human kinome, producing negligible inhibition of any kinase
tested (Supplementary Table 1). Moreover, the rest of inhibitors
used can be categorized as highly selective inhibitors of their
PI3K/AKT pathway main targets (Fig. 2b) attending to published
reports. The detailed selectivity information can be accessed in
the references cited above and additional complementary studies:
ETP-4699266; GDC-094167, and (http://lincs.hms.harvard.edu/db/
datasets/20060; http://lincs.hms.harvard.edu/db/datasets/20261);
BKM-12068 and (http://lincs.hms.harvard.edu/db/datasets/
20262); BYL-71969, 74 and (http://lincs.hms.harvard.edu/db/
datasets/20263); TGX-22170 and (http://lincs.hms.harvard.edu/
db/datasets/20223); BEZ-23571 and (http://lincs.hms.harvard.
edu/db/datasets/20096); and GSK-212645873 and (http://lincs.
hms.harvard.edu/db/datasets/20084).
Next, we measured the inhibition of PI3Kα activity by these
compounds in the CHA-9.3 cell line by determining the
phosphorylation of AKT (p-AKT S473) at 24 h after treatment
with 10 μM concentration of each compound, except for GSK-
2126458, which was dosed at 1.0 μM due to its high cytotoxicity
at 10 μM. As shown in Fig. 2c, phosphorylation of AKT in the
CHA-9.3 cell line was strongly reduced by all these molecules
with the exception of TGX-221, which only showed a moderate
inhibition. In these conditions, all these PI3K inhibitors,
independently of their structure and their mTOR activity, were
able to inhibit TRF1 foci (Fig. 2d), confirming a role of the PI3K
signaling pathway in TRF1 regulation, which is independent of
mTOR inhibition. As a general trend, the strongest inhibition of
p-AKT (S473) correlated with the highest downregulation of
TRF1 foci, being the TGX-221 compound the weakest TRF1
inhibitor and also the one exerting the weakest p-AKT inhibition
(Fig. 2d). Importantly, the specific inhibitor for the p110α
isoform, BYL719, efficiently inhibited TRF1 foci (30%), whereas
the specific inhibitor for the p110β isoform TGX221 only
decreased by 10% TRF1 foci fluorescence (Fig. 2d). These results
indicate that the PI3K isoform p110α is the main activity involved
in TRF1 regulation at telomeres and that mTOR inhibition is not
necessary.
We next studied the direct effect of AKT inhibition on TRF1
foci formation. To this end, we treated CHA-9.3 cells with the
previously described allosteric AKT inhibitor MK-220672 at 10
μM concentration (Fig. 2a–d). Similarly to PI3Kα inhibitors, MK-
2206 effectively inhibited TRF1 foci, which correlated with strong
inhibition of p-AKT at Ser473 (Fig. 2c, d).
We then checked whether PI3Kα/AKT inhibition also leads to
decreased TRF1 foci in an additional cell type to CHA-9.3 cells.
Thus, we used p53−/− mouse embryo fibroblasts (MEF). We
treated these MEFs either with the AKT inhibitor MK-2206 or
with ETP-47037 at 10 μM concentration for 24 h and analyzed
TRF1 foci by immunofluorescence. The results clearly show that
both the AKT inhibitor and our ETP-47037 proprietary
compound induce a 22% and 34% reduction in TRF1 foci
intensity, respectively (Fig. 3a).
Together, these results demonstrate that the PI3K(p110α)-AKT
pathway is involved in TRF1 regulation, while the downstream
kinase mTOR is not necessary for this inhibition.
Depletion of the p110α isoform of PI3K reduces TRF1 foci.
Next, we used a genetic approach to validate the above-described
chemical data indicating that the PI3K p110α isoform is the one
responsible for inhibition of TRF1 foci. To this end, we used the
Cre-LoxP mediated recombination system to conditionally inac-
tivate either the PIK3CA or PIK3CB genes encoding the p110α
and p110β catalytic subunits, respectively, in the corresponding
immortalized p110α (lox/lox) and p110β (lox/lox) MEFs75
(“Methods” section). We first infected the conditional knockout
MEFs with adenovirus simultaneously expressing Cre recombi-
nase and GFP (Adeno-Cre-GFP). In this manner, the GFP-
positive cells will also express Cre, thus marking those cells that
carry each PIK3C gene deletion. We next quantified TRF1 foci by
immunofluorescence in both GFP-positive and GFP-negative
cells (Fig. 3b, c). In agreement with the chemical inhibitor data
(Figs 2d and 3a), genetic ablation of the gene encoding the p110α
catalytic subunit but not of the one encoding p110β catalytic
subunit strongly inhibited TRF1 foci intensity (Fig. 3b, c; note
that eGFP-positive cells deleted for p110α but not for p110β show
dramatically decreased TRF1 foci in the representative images). In
summary, both chemical and genetic inhibition approaches
demonstrate that formation of TRF1 foci is regulated by PI3Kα
but not by the PI3Kβ isoform.
PI3K-AKT inhibition leads to telomere fragility. Trf1 abroga-
tion is known to lead to a persistent DDR at telomeres, and to
induction of telomere-induced chromosomal aberrations28–30. Trf1
genetic deletion induces the so-called multitelomeric signals (MTS),
a chromosomal aberration related to increased telomere fragility
during DNA replication28, 29. In agreement with their activity
against TRF1 foci, we previously demonstrated that the ETP-47037
and ETP-47228 inhibitors can also induce formation of MTS in
IPSCs (IPSC)39. Here, we set out to demonstrate a direct role of
PI3K inhibition in the induction of MTSs provoked by PI3K
inhibitors. To this end, we treated CHA 9-3 cells with either DMSO,
the AKT inhibitor MK-2206 (AKTi) and the PI3K inhibitors ETP-
47037 or ETP-47228. For detection of MTS, we performed quan-
titative fluorescence in situ hybridization (Q-FISH) analysis on
metaphase spreads using a telomeric probe to visualize telomeres
(“Methods” section). MTS are visualized by presenting a multi-dot
pattern at chromosome ends in contrast to normal telomeres that
show a single dot at each chromosome end. In agreement with their
activity against TRF1 foci, treatment with ETP-47037, ETP-47228
and with AKTi significantly increased the frequency of MTS events
per metaphase compared to DMSO-treated cells (Fig. 3d, e).
We next set to genetically validate these findings using
immortalized p110αlox/lox MEFs transduced with Cre recombi-
nase to induced P110α deletion. MTS were determined in
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Fig. 2 TRF1 regulation by PI3K and AKT inhibitors. a Structurally diverse PI3K and PI3K/mTOR inhibitors used in the study. b PI3K and mTOR data
generated internally and reported in literature. c Representative western blot images of phosphorylated AKT-Ser473 and total AKT in CHA-9.3 mouse lung
tumor cell line at 24 h after treatment with PI3K, AKT, and mTOR inhibitors as indicated. d Percent inhibition of TRF1 foci by immunofluorescence and of
AKT phosphorylation at S473 (pAKT) in CHA-9.3 mouse lung tumor cell line at 24 h after treatment with the indicated inhibitors relative to TRF1 levels and
to pAKT levels in control cells treated with DMSO. The inhibitors were tested at 10 μM except GSK-2126458 that was used at 1.0 μM (in c and d). Error
bars represent standard deviation. The Student’s t test was used for statistical analysis; P values are shown. n number of independent experiments
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chromosome spreads as described above. Conditional p110αlox/lox
MEFs were transduced with either Cre or GFP. In agreement with
the results shown with PI3K and AKT chemical inhibitors, p110α
deletion induced a significant threefold increase in the incidence
of MTS compared to GFP transduced cells (Fig. 3f).
The PI3K-AKT pathway regulates TRF1 protein levels. We
investigated whether TRF1 inhibition by PI3K and AKT inhibi-
tors was occurring at the level of TRF1 transcription or at the
post-transcriptional level. To this end, CHA 9-3 lung cancer cells
were incubated with 10 μM of PI3K inhibitors (ETP-47037 and
GDC-0941) or AKT inhibitor (MK-2206) for a total of 24 h. None
of the inhibitors significantly affected TRF1 mRNA levels (Sup-
plementary Fig. 2a). As genetic validation, we also found normal
Trf1mRNA levels in MEFs genetically deleted for P110α, the gene
encoding PI3Kα (Supplementary Fig. 2b), thus indicating that
regulation of TRF1 foci by PI3K/AKT does not occur at the
transcriptional level. Next, we performed western blot analysis to
determine whether PI3K/AKT could regulate TRF1 protein levels
(Fig. 4a). Interestingly, chemical inhibition of either AKT (using
the MK-2206 AKTi) or PI3K (using ETP-47037 and ETP47228)
lead to significantly decreased TRF1 protein levels in nuclear
extracts (Fig. 4a).
We confirmed these findings using p53−/− MEFs as an
independent cell type. Treatment of these MEFs with the PI3K
ETP-47037 or with the AKT inhibitor MK-2206 also showed
decreased total nuclear TRF1 levels compared to cells treated with
DMSO (Fig. 4b).
These findings were further validated genetically using
immortalized p110αlox/lox MEFs. P110αlox/lox MEFs transduced
with Cre recombinase showed decreased total nuclear TRF1 foci
fluorescence compared to non-transduced cells (Fig. 4c).
Together, these findings indicate that PI3K/AKT inhibitors
decrease TRF1 protein levels. We next explored whether
inhibition of the proteasome by bortezomib could rescue TRF1
protein levels. Bortezomib treatment lead to a twofold increase in
TRF1 intensity levels in CHA 9-3 cells (Fig. 4d). However,
combined treatment of CHA 9-3 cells with bortezomib and PI3K
inhibitors ETP-47037, ETP-47228, or with the AKT inhibitor
MK-2206 resulted in significantly lower TRF1 levels as compared
to bortezomib/DMSO-treated control cells suggesting that PI3K/
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Fig. 3 TRF1 telomeric levels are regulated by p110α. a Quantification of mean TRF1 foci intensity by immunofluorescence of immortalized p53−/− MEFs
were treated either with DMSO, AKT inhibitor (AKTi), or with ETP47037. b Quantification of mean TRF1 foci intensity by immunofluorescence in p110α
(lox/lox) and p110β (lox/lox) MEFs infected with Adeno-CRE-GFP. The graph shows quantification of TRF1 foci in both infected (Ad-CRE-GFP) and non-
infected (negative) cells. c Representative TRF1 (red) and GFP (green) immunofluorescence images. Scale bars are shown. d Incidence of multitelomeric
signals (MTS) events in metaphase spreads of lung cancer-derived cells (CHA 9-3) treated either with DMSO, AKT inhibitor (AKTi) (10 μM), ETP47037
(10 μM), or ETP47228 (10 μM). e Representative images of metaphase spread corresponding to DMSO- and to ETP47037-treated cells. MTS are labeled
with a white arrow head. Zoomed images are shown in the insets. Scale bars are shown. f Incidence of multitelomeric signals (MTS) events in metaphase
spreads of immortalized P110αlox/lox MEFs either transduced with GFP or with Cre recombinase. (n) Analyzed metaphases in each condition. The Student’s
t test was used for statistical analysis; P values are shown. Error bars represent standard deviation. n number of independent experiments
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ADP-ribosylation of human TRF1 by tankyrase 1 releases
TRF1 from telomeres, which serves as a signal for its
ubiquitination and subsequent degradation16, 19. Although the
mouse TRF1 lacks the canonical Tankyrase 1 binding site and has
been previously reported not to be a substrate for tankyrase 1 poly
(ADP-rybosyl)sylation in vitro76, here we nevertheless tested
whether a Tankyrase inhibitor was able to abrogate the effects
induced by PI3K inhibitors. However, in agreement with previous
reports, a tankyrase inhibitor did not rescue TRF1 down-
regulation by PI3K inhibitors (ETP-47037) (Supplementary
Fig. 3).
Purified TRF1 is directly phosphorylated by AKT. To address
whether TRF1 is a direct substrate of AKT, affinity purified GST-
TRF1 was incubated with purified human AKT1 (1379-0000-2,
ProQinase) in the presence of γ-32ATP. As positive control, a
GSK3 (14-27) peptide (0349-0000-5, prokinase) was also used as
substrate. AKT1 yielded a TRF1 phosphorylation signal after
incubation with purified GST-TRF1 during 1 h, which was
decreased in the presence of AKT inhibitor (see asterisk in Fig. 5a,
left). AKT1 also yielded a phosphorylation signal in the positive
control peptide GSK3 (14-27) that was reduced in the presence of
AKT inhibitor (Fig. 5a, right). An autophospholyration activity of
AKT1 was detected after 1 h of incubation and this activity was
reduced in the presence of AKT inhibitor (Fig. 5a). Together,
these findings indicate that TRF1 is a direct substrate of AKT1.
We next set to identify the specific TRF1 phosphorylation sites
by AKT. To this end, we analyzed phosphopeptides by liquid
chromatography-mass spectrometry (LC/MS/MS) analysis in
TRF1 and TRF1&AKT1, samples containing ATP (“Methods”
section). We identified two different TRF1 phosphopeptides in
samples containing AKT1. One peptide presented threonine 330
(T330) and the other contained phosphorylated threonine 248
(T248) (Fig. 5b–e). As expected, no phosphopeptides were
identified in the sample containing only TRF1 (Fig. 5d, e). Of
note, human TRF1 has been shown to be phosphorylated by AKT
at residue T273, which corresponds to residue S344 in mouse
TRF124. However, this potential TRF1 phosphorylation site in
residue S344 was not identified in our LC/MS/MS analysis, most
likely due to the fact that this site is located between two close
























































































































































































































































































Fig. 4 PI3K/AKT inhibitor post-translationally downregulate TRF1 levels. a Quantification of total nuclear TRF1 levels in lung cancer-derived cells (CHA 9-3)
treated either with DMSO, AKT inhibitor (AKTi) (10 μM), ETP47037 (10 μM), or ETP47228 (10 μM). A representative western blot image is shown below.
b Quantification of total nuclear TRF1 levels in in immortalized p53−/− MEFs treated either with DMSO, AKT inhibitor (AKTi) (10 μM), or ETP47037 (10
μM). A representative western blot image is shown below. c Quantification of total nuclear TRF1 levels in P110αlox/lox MEFs cells transduced with pBabe-
GFP or with pBabe-Cre recombinase. A representative WB images is shown below. d Quantification by immunofluorescence of mean TRF1 foci intensity in
CHA 9-3 cells treated either with DMSO, DMSO plus bortezomib (50 nM), ETP47037 (10 μM) plus bortezomib (50 nM), ETP47228 (10 μM) plus
bortezomib (50 nM), and AKTi (10 μM) plus bortezomib (50 nM). Student’s t test was used for statistical analysis; P values are shown. Error bars
represent standard error. n number of independent experiments
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peptide (TSGR) too short to be detected by conventional
LC/MS/MS.
In order to in vitro validate these phosphorylation sites
including the S344 residue, we generated GST-tagged Trf1 alleles
where either the T248, T330, or S344 residues were mutated to
alanine. We also generated a GST-Trf1 allele that contained the
triple substitution T248A/T330A/S344A (Fig. 5f). Affinity
purified GST-TRF1, GST-TRF1T330A, GST-TRF1S344A, GST-
TRF1T248A, and GST-TRF1T330A/S344A/T248A were incubated
with purified human AKT1 in the presence of γ-32ATP (Fig. 5g).
We found significantly decreased levels of phosphorylated-TRF1
in the variants harboring T330A and S344A substitutions
compared to wild-type TRF1 (Fig. 5g). The T248A substitution
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phosphorylation levels by AKT1 although the difference did not
reach statistical significance (Fig. 5g). In summary, AKT1-
dependent phosphorylation of TRF1 is reduced by mutation of
T330 and S344 residues and to a lesser extent by mutation of the
T248 residue. Of note, the observation that there is a detectable
phosphorylated-TRF1 signal in the absence of the identified AKT
phosphorylation sites (triple mutant TRF1T330A/S344A/T248A) may
indicate the presence of additional sites within TRF1.
TRF1 phosphorylation by AKT required for TRF1 foci for-
mation. Finally, to address the in vivo role of these TRF1 mod-
ifications by AKT1, we transduced eGFP-tagged Trf1 wild-type
and mutant alleles in both primary p53-deficient MEFs
(Trf1T248A, Trf1T330A, Trf1S344A, Trf1T330A/S344A, and Trf1T248A/
T330A/S344A mutants) and in CHA 9-3 lung cancer cells
(Trf1T330A, Trf1S344A, and Trf1T330A/S344A mutants) (Fig. 6a). The
mean GFP spot fluorescence intensity per cell was quantified by
using Opera high-content screening (HCS) (Fig. 6a). In MEFs, we
found that the TRF1 single mutants T330A and S344A, as well as
the TRF1 double and triple mutants (T330A/S344A and T248A/
T330A/S344A) showed a significant decrease in the intensity of
TRF1 telomeric foci fluorescence compared to MEFs expressing
wild-type TRF1 (Fig. 6b, d). Similarly, in CHA 9-3 cells, the
intensity of TRF1 telomeric foci fluorescence was significantly
decreased in cells expressing the TRF1 mutants T330A, S344A,
and T330/S344A, thus confirming the results obtained in MEFs
(Fig. 6c, d).
In order to rule out potential interference of the GFP-tagged
TRF1 variants with the endogenous TRF1, we transduced eGFP-
tagged Trf1 wild-type and mutant alleles in p53−/− Trf1lox/lox
MEFs (Trf1T248A, Trf1T330A, Trf1S344A, and Trf1T330A/S344A
mutants) and then deleted the endogenous Trf1 by transduction
with the Cre recombinase. Overexpression of eGFP-Trf1 alleles
and complete deletion of the endogenous Trf1 was confirmed by
western blot analysis using a specific TRF1 antibody (Fig. 6e).
Quantification of mean GFP spot fluorescence intensity in
Trf1−/− MEFs confirmed that the TRF1 single mutants T330A
and S344A, as well as the TRF1 double mutant (T330A/S344A)
showed a significant decrease in the intensity of TRF1 telomeric
foci compared to MEFs expressing wild-type TRF1 (Fig. 6f). In
contrast, no significant differences were detected between TRF1-
T248A and wild-type TRF1 (Fig. 6f). In order to address the
ability of these mutant variants to rescue the severe proliferative
defects associated to TRF1 deficiency28, 29, we analyzed growth
rate in Trf1-deficient MEFs expressing eGFP-tagged Trf1wt,
Trf1T248A, Trf1T330A, and Trf1S344A alleles (Fig. 6g). We found
that cells expressing TRF1-T330A and TRF1-S344A did not
rescue impaired proliferation in Trf1-deleted cells, indicating that
these mutant TRF1 proteins are non-functional in their ability to
complement proliferation defects in TRF1-deleted cells. In
contrast, cells expressing TRF1-T248A grew at similar rate than
TRF1 wild-type cells, suggesting that TRF1-T248A variant has no
major impact on TRF1 function (Fig. 6g).
These observations are in agreement with the in vitro
phosphorylation data of TRF1 by AKT1 in which T330A,
S344A, and T248A/T330A/S344A mutants rendered reduced P-
TRF1 levels (Fig. 5g). These results indicate that AKT1 specifically
phosphorylates TRF1 at T248, T330, and at S344, and that
mutation of T330 and S344 but not of T248 sites to non-
phosphorylatable alanine residues impairs proper TRF1 function.
AKT regulates TRF1 half-life and binding to telomeres.
Decreased AKT-mediated TRF1 phosphorylation results reduc-
tion of total TRF1 protein amounts (Fig. 4) and in decreased of
TRF1 foci (Figs 1d, 2d, 3a, b and 6b–e). We envisioned at least
two scenarios in which AKT-mediated TRF1 phosphorylation
could be regulating TRF1 levels at telomeres. On the one hand,
AKT-mediated phosphorylation of TRF1 may regulate
TRF1 stability and turn-over. On the other hand, AKT-mediated
phosphorylation of TRF1 might also regulate TRF1 binding to
telomeres, either by affecting TRF1 dimerization and/or TRF1
telomeric DNA-binding capacity77. To address the mechanisms
underlying PI3K/AKT-dependent TRF1 regulation, we first ana-
lyzed the half-life of the GFP-tagged wild-type and non-
phosphorylatable T248A, T330A, S344A, and T330A/S344A
TRF1 variants. The results showed that all the mutant proteins
present a twofold reduction in their half-life (HL <2.5 h) as
compared to wild-type TRF1 (HL= 4.5 h), indicating that AKT-
mediated phosphorylation is involved in TRF1 stability (Fig. 7a).
To address the dimerization capability of the non-
phosphorylatable TRF1 mutants, we performed western blot
analysis of nuclear cell extract of Trf1-deleted MEFs expressing
GFP-tagged wild-type and T248A, T330A, S344A, and T330A/
S344A TRF1 variants in non-reducing conditions (Fig. 7b). While
in reducing conditions GFP-TRF1 renders a 70 KD band, in non-
reducing conditions without DTT a band of approximately 140
kD was detected in GFP-TRF1 wild-type and all the mutant
variants analyzed, corresponding to TRF1 dimers. The results
clearly show that none of these mutations affect the dimerization
capacity of TRF1 (Fig. 7b).
We next sought to determine whether the non-
phosphorylatable TRF1 mutant proteins were affected in their
ability to bind telomeric DNA. To this end, affinity purified GST-
TRF1, GST-TRF1T330A, GST-TRF1S344A, and GST-TRF1T248A
were incubated with radiolabeled telomeric DNA and with
TRF1 specific antibody. Visualization of the protein-DNA
complexes by electrophoretic mobility shift assay (EMSA)
confirmed that wild-type TRF1 and TRF1T248A efficiently bound
telomeric DNA, whereas GST-TRF1T330A and GST-TRF1S344A
bound telomeric DNA less efficiently (Fig. 7c), in agreement with
Fig. 5 TRF1 is phosphorylated in vitro by AKT1. a One μg of purified GST-TRF1 was incubated with 0.2 μg of human GST-AKT1 with or without AKT inhibitor
(MK-2206) in kinase buffer containing 5 μCi [γ-32-P]ATP (left). The peptide RBER-GSK3(14-27) was used as positive controls (right). The reaction
mixtures were resolved by SDS-PAGE and subjected to autoradiography. b MS/MS spectrum of unmodified TRF1 328-339 (above panel) and of the TRF1
328-339 peptide in which phosphorylation was assigned to T330 residue (below panel). c MS/MS spectrum of unmodified TRF1 246-255 peptide and of
the TRF1 246-255 peptide in which phosphorylation was unambiguously assigned to the T248 residue (below panel). Mass error, identification score, and
posterior error probability (PEP) are shown for the different peptides. d, e Quantification of TGTLQCETTMER (T330) (d) and of the AATKVVENEK (T248)
(e). Phosphopeptide peak intensity normalized to total TRF1 signal in samples containing only TRF1 or TRF1 plus AKT1. f Schematic representation of TRF1
protein depicting its N-terminal acidic domain, TRFH domain, nuclear localization signal (NLS), and its Myb domain. The residues found phosphorylated by
AKT (T248, T330, and S344) were mutated to alanine. g Representative image of in vitro phosphorylation assay of purified GST-TRF1, GST-TRF1(T330A),
GST-TRF1 (S344A), GST-TRF1 (T248A), or GST-TRF1 (T330A/S344A/T248A) by GST-AKT1. The reaction mixtures were resolved by SDS-PAGE and
subjected to autoradiography. As loading control, purified GST-TRF1 protein samples were run in SDS-PAGE and coomassie-stained (below panel). The
quantification of mutant P-TRF1 levels normalized to wild-type TRF1 is shown to the right. Student’s t test was used for statistical analysis, P values are
shown. Error bars represent standard deviation. n number of independent experiments
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Fig. 6 Phosphorylation of T248, T330, and S344 in TRF1 stabilizes TRF1 telomeric foci. a Retroviral infection of eGFP-tagged Trf1 WT or mutant alleles
(Trf1T248A, Trf1T330A, Trf1S344A, Trf1T330A/S344A, and Trf1T248A/T330A/S344A) was performed to overexpressed depicted TRF1 variants. The mean GFP spot
intensity per cell was quantified by Opera high-content screening (HCS). b, c Quantification of the decrease in mean GFP-TRF1 spot telomeric intensity in
transduced wild-type MEFs (b) and in CHA 9-3 cells (c). The percent change in mean intensity of TRF1 mutant variants was represented relative to wild-
type TRF1. d Representative eGFP-TRF1 immunofluorescence images. Scale bars are shown. e Trf1lox/lox MEFS with or without overexpression of eGFP-Trf1
WT or mutant (Trf1T248A, Trf1T330A, Trf1S344A, and Trf1T330A/S344A) alleles were transduced with the Cre recombinase to delete endogenous Trf1. As
controls, Trf1lox/lox and Trf1lox/lox overexpressing WT eGFP-TRF1 were infected with pBabe. Expression of the eGFP-TRF1 variants and of endogenous TRF1
was determined by western blot using a specific TRF1 antibody. f Quantification of the decrease in mean GFP-TRF1 spot telomeric intensity in transduced
Trf1Δ/Δ deleted MEFs. g Growth rate of Trf1Δ/Δ deleted MEFs overexpressing eGFP-tagged Trf1WT and mutant alleles as indicated. Student’s t test was used
for statistical analysis and P values are shown. Error bars represent standard errors. n number of independent experiments
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-01329-2
10 NATURE COMMUNICATIONS | 8:  1278 |DOI: 10.1038/s41467-017-01329-2 |www.nature.com/naturecommunications
the in vitro TRF1 phosphorylation data (Fig. 5f, g) and the in vivo
TRF1 foci formation and cell proliferation data (Fig. 6a–g).
Specificity of the protein-DNA complexes was demonstrated by
the supershift observed upon addition of TRF1 antibody to the
reaction (Fig. 7c).
These results indicate that AKT1-mediated phosphorylation of
TRF1 at T330 and at S344 regulate TRF1 protein stability and are
required for proper TRF1 telomeric DNA binding and cell
viability.
Decreased TRF1 levels in PDXs treated with PI3Kα inhibitor.
We next set to address whether PI3Kα inhibition in human tumor
samples showed decreased TRF1 levels compared to untreated
controls. To this end, we generated PDXs from seven independent
CHX (h): 0 1 2.5 4 5











































































































































Fig. 7 AKT-mediated TRF1 phosphorylation regulate TRF1 protein stability and telomeric DNA-binding ability. a TRF1 protein half-life (HL) was determined
in MEFs overexpressing eGFP-Trf1WT or mutant (Trf1T248A, Trf1T330A, Trf1S344A, and Trf1T330A/S344A). Cells were pre-treated with 100 µg/ml cyclohexamide
(CHX) or bortezomib (5 µM) for 30min. At the indicated times, the cells were collected to prepare nuclear extracts, followed by western blot analysis
against TRF1 or SMC1 (as loading control) (left). The graph represents the mean value for each time point and corresponding standard deviation (right
panel). P values are indicated. b Trf1lox/lox MEFS with or without overexpression of eGFP-Trf1 WT or mutant (Trf1T248A, Trf1T330A, Trf1S344A, and Trf1T330A/
S344A) alleles were transduced with the Cre recombinase to delete endogenous Trf1. As control, Trf1lox/lox MEFs overexpressing WT eGFP-TRF1 was
infected with pBabe. Nuclear protein extracts were prepared in non-reducing conditions (without DTT) to detected TRF1 dimers. Western blot against TRF1
was performed in non-reducing conditions without heating in SDS-PAGE. A single sample corresponding to WT-TRF1 was loaded in reducing conditions to
show the monomeric form of TRF1. Ponceau staining is shown as loading control (below panel). c In vitro TRF1 binding to telomeric dsDNA (TTAGGG)7
assay was performed with GST-tagged TRF1 WT and mutant variants (T330A; S344A and T248A) as indicated by electrophoretic mobility shift assay
(EMSA). Arrows show the positions of the three TRF1-containing complexes observed. As control for specificity of TRF1/DNA interactions, specific TRF1
antibody was also added to the reaction to obtain a supershift
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ER/Her2-positive breast cancer patients in female athymic NMRI
nu/nu mice, and treated these with either the PI3Kα specific inhi-
bitor BYL719 (35mg/k 6IW) or with vehicle during a total of
12 days. Mice were then killed and PDXs extracted and formalin
fixed for further analysis. A TRF1 immunofluorescence followed by
a telomere quantitative q-FISH was performed in PDXs sections to
identify TRF1 specifically located at telomeres by co-localization of
TRF1 protein to telomeric DNA, as well as to quantify telomere
length. Telomeric TRF1 foci at telomeres (green spots) were
unequivocally identified by co-localization with telomeric PNA
probe (red spots) (Fig. 8a). Quantification of telomeric TRF1 spot
intensity by immunofluorescence in seven independent PDXs (in
duplicates) showed that TRF1 levels significantly decreased in 4 out
of 7 PDX (PDX 153, PDX131, PDX313, and PDX244), increased in
2 out of 7 PDX (PDX39 and PDX191), and remained unchanged in
one PDX (PDX98) (Fig. 8a, b). Immunohistochemistry staining of
phosphorylated AKT (S473) in these same PDXs followed by
quantification of tumor positive area was performed to address the
efficacy of BYL719 treatment (Fig. 8c, d). In 4 out of 7 PDXs
(PDX153, PDX313, PDX98, and PDX244) BYL719 treatment
induced a decrease in pAKT (S473) as compared to vehicle treated
controls, indicating efficacy in PI3K pathway inhibition. These four
PDXs were considered as “responders” to the PI3Kαi treatment.
Two PDXs, PDX131 and PDX39, were negative for pAKT at basal
levels (before treatment with the PI3Ki BYL719) and remained
unchanged upon BYL719 treatment. Interestingly, PDX191 showed
a significant 46% increase in pAKT levels and 80% increase in
telomeric TRF1 levels in treated samples as compared to untreated
controls. This unexpected increase in pAKT levels of PDX191 upon
BYL719 treatment could be explained by the activation of regulatory
feedback loops that trigger compensatory signaling events leading to
activation of the AKT pathway78. These three PDX (PDX131,
PDX39, PDX191) were considered as “non-responders” to the
treatment with the PI3Kα inhibitor BYL719. Of note, in 3 of the 4
responders (PDX153, PDX313, and PDX244) the telomeric TRF1
levels significantly decreased after BYL719 treatment while in the
other PDX (PDX98) the TRF1 levels remained the same. It should
be pointed out that untreated PDX131 and PDX39 that presented
undetectable pAKT levels correspond to those samples with the
lowest telomeric TRF1 levels (Fig. 8b, d). Quantification of mean
telomere length in these PDX samples showed moderate but sig-
nificant changes in mean telomere length upon BYL719 treatment.
Thus, TRF1 levels correlated significantly both with telomere length
and with pAKT (S473) levels, although the correlation was more
significant in the case of pAKT(S473) levels (Fig. 8f). In addition, the
telomere length changes were more moderate as compared to
changes observed in TRF1 levels.
Decrease in pAKT (S473) levels and the concomitant decrease in
TRF1 foci signal in the “responder” PDXs following treatment with
the PI3Kα inhibitor BYL719 was accompanied with a significant
increase in cells presenting DNA damage (γH2AX positive cells)
(Fig. 8g). We also observed a higher number of telomere-induced
DNA damage foci (TIFs) in the BYL719-treated “responder”
tumors than in the “non-responders” (Fig. 8h, i), in agreement with
lower levels of telomere bound TRF1 levels in the “responders”
(Fig. 8b, d). These findings suggest that TRF1 inhibition also occurs
in human tumor samples upon efficient inhibition of PI3Kα, thus
pinpointing TRF1 as a relevant target of PI3K inhibitors, which
leads to increase DNA damage at telomeres.
Discussion
Telomeres are essential to maintain genome stability. TRF1 is an
essential component of shelterin, the telomere protective com-
plex. TRF1 has a fundamental role in protecting telomeres from
DNA repair activities and from replication-induced fragility, thus
preventing telomeric DNA damage28, 29. In a previous work, we
identified two small molecules that disrupt TRF1 telomeric foci,
however, the mechanism of action remained unknown39. Here,
we demonstrate that these compounds regulate TRF1 location to
telomeres throughout inhibition of the PI3K/AKT pathway. In
particular, we show that inhibition of PI3K and AKT by using
small molecules, or by genetic depletion of the gene encoding the
PI3Kα subunit (p110α), leads to decreased TRF1 protein levels
and decreased TRF1 telomeric foci. Furthermore, cells treated
with PI3K/AKT inhibitors show increased number of telomere
aberrations and telomere-induced DNA damage. Importantly,
patient-derived PDX models treated with PI3K inhibitors that
showed efficient downregulation of the PI3K pathway also show
decreased TRF1 levels and increased telomere-induced DNA
damage. These findings pinpoint TRF1, and its role in preventing
telomere damage, as one of the targets of the PI3K/AKT pathway,
with important implications both for cancer and aging-related
therapeutic strategies.
Human AKT1 has been previously shown to interact with
TRF1 and to phosphorylate TRF1 at threonine 272 by AKT24.
Overexpression of AKT in HTC cells was also shown to induce
upregulation of TRF1 protein levels and telomere shortening24. In
contrast, here we show that lower pAKT levels before or after
treatment of patient-derived PDX models of breast cancer with a
PI3K/AKT inhibitor, correlates with lower TRF1 levels and
shorter telomeres, although telomere length changes are more
moderate compared to changes in TRF1 levels upon inhibition of
the PI3K/AKT pathway. Thus, although it has been shown that
long-term overexpression of TRF1 in human cells results in
progressive telomere shortening79, and TRF1 overexpression in
transgenic mice also leads to telomere shortening in a XPF
nuclease-dependent manner80, here we observe longer telomeres
in PDXs presenting higher endogenous TRF1 levels compared to
those with lower TRF1 levels. This apparent discrepancy may be
explained by the fact that in our setting TRF1 is not necessarily
overexpressed, and higher levels of TRF1 in PDX with longer
telomeres may reflect on the normal binding of TRF1 along
longer tracts of telomeric repeats. In fact, Trf1 deletion or inhi-
bition of TRF1 protein levels in mouse does not lead to telomere
length changes but induces telomere de-protection/
damage28, 29, 39. Nevertheless, future studies using a larger set of
patient samples are needed for addressing the relationship
between PI3K/AKT pathway and telomere length. Importantly,
we show here a correlation between lower pAKT levels and
decreased TRF1 protein localizing at telomeres in the PDX
models that respond to the Pi3K/AKT inhibitors. Also,
“responder” tumors show increased telomere-induced damage in
agreement with telomere uncapping as the consequence of
decreased TRF1 levels.
Here we demonstrate that AKT1 directly phosphorylates pur-
ified mouse TRF1 at various previously un-identified residues. In
particular, by using in vitro phosphorylation assays, we identify
Threonine 330 (T330) and Threonine 248 (T248) as bona fide
AKT1 phosphorylation sites in mouse TRF1. In addition, we
show that AKT1 also phosphorylates mouse TRF1 at Serine 344,
which is the analogous site to human TRF1 residues Threonine
271 and Threonine 273, recently shown to be necessary for TRF1
binding to telomeres24, 81. Furthermore, we show that substitu-
tion of these residues in mouse TRF1 to non-phosphorylatable
alanine residues in S344A and T330A mutants results in sig-
nificantly reduced levels of in vitro AKT1-dependent TRF1
phosphorylation. An analogous trend to decreased AKT1-
dependent phosphorylation was found for the T248A mutant
although it did not reach statistical significance. These results
demonstrate that residues S344 and T330, and to a lesser extend
residue T248, in mouse TRF1 are bona fide AKT1 targets.
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Fig. 8 Inhibition of PI3Kα decreases TRF1 levels and increases telomeric DNA damage in human PDXs. a Representative immunoFish images of TRF1
immunofluorescence and telomeric DNA FISH of vehicle and BYL719-treated PDXs. Seven independent tumors were used to generate PDXs in duplicate
per condition. Scale bars are shown. b Quantification of telomeric TRF1 foci intensity by immunofluorescence in seven independent PDXs treated either
with vehicle or with BYL719 for 12 days. Telomeric TRF1 foci were identified by colocalization with telomeric DNA by FISH. The percent change in telomeric
TRF1 intensity in treated PDXs as compared to non-treated are indicated in each case. Seven independent tumors were used to generate PDXs in duplicate
per condition. c Representative immunohistochemistry images of phosphorylated AKT (S473) in PDXs treated with either vehicle or with BYL719. Scale
bars are shown. d Quantification of pAKT (S473) positive area with regards to total tumoral area in each PDX. Scale bars are shown. The efficacy of the
treatment was analyzed by quantifying the percent inhibition of pAKT (S473) as compared to vehicle treated controls and is indicated in each case. e
Quantification of mean telomere length by Q-Fish in PDXs treated either with vehicle or with BYL719 for 12 days. f Pearson correlation analysis between
telomeric TRF1 foci intensity and pAKT or mean telomere length of untreated and BYL179 treated PDXs. The Pearson r coefficient and the P values are
indicated. g, h Number of positive γH2AX cells (≥3 foci) (g) and quantification of telomere-induced foci (TIFs) by double immunofluorescence with anti-
RAP1 and anti-γH2AX antibodies (h) in PDXs treated either with vehicle or with BYL719 for 12 days. The PDXs were grouped in non-responders or
responders according to the efficacy of BYL179 treatment as measured in d. i Representative RAP1 and γH2AX immunofluorescence images of vehicle and
BYL719-treated PDXs. Damage cells (green) are marked with a white arrow and TIFs (yellow) with a yellow arrow head. Scale bars are shown. Student’s t
test was used for statistical analysis and P values are shown. Error bars represent standard errors. n number of independent experiments
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Importantly, overexpression of all three eGFP-tagged TRF1
mutants in vivo, showed that T330A and S344A mutations sig-
nificantly reduced telomeric eGFP-TRF1 foci in vivo, suggesting
that AKT1-dependent phosphorylation of these sites is important
for TRF1 binding to telomeres. Indeed, we show that these
modifications regulate TRF1 stability and telomeric DNA bind-
ing. One the one hand, the half-life of non-phosphorylatable
mutant proteins (T248A, T330A, and S344A) is reduced more
than twofold as compared to wild-type TRF1, demonstrating that
AKT-mediated phosphorylation is involved in TRF1 turn-over.
On the other hand, we also show that TRF1-T330A and TRF1-
S344A bound telomeric DNA less efficiently as compared to wild-
type TRF1, demonstrating that these phosphorylations (T330 and
S344) regulate proper TRF1 telomere binding. Indeed, neither
TRF1-T330A nor TRF1-S344A variants were able to complement
the severe proliferative defects of Trf1-deficient cells, indicating
that these sites are important for TRF1 function in vivo. The
observation that TRF1-T248A was able to complement Trf1
deficiency to a similar degree than wild-type TRF1, even though
showed a shorter half-life in turn-over experiments, might be
explained by the fact that the complementation assay was per-
formed with overexpressed proteins thus the effects on protein
stability maybe masked. Further studies using knock-in mouse
models warrants further clarification of the in vivo phenotypic
consequences of these mutations.
Pathologic activation of the PI3K pathway is among the most
frequent signaling events associated with cellular transformation,
cancer and metastasis42, 43. The PI3K pathway regulates a wide
range of target proteins to control cell proliferation, survival,
apoptosis and cell growth40. In the last years, pharmaceutical
interest has arisen to develop strategies to inhibit PI3K signaling
in cancer cells. Several PI3K downstream targets have been pro-
posed to mediate the role of PI3K in cancer45, 46. Our results
suggest that induction of telomere DNA damage upon PI3K
inhibition constitutes another mechanism underlying the anti-
cancer effects of PI3K/ATK chemical inhibitors. Indeed, treat-
ment of mice suffering from aggressive lung cancer in vivo with
the ETP-47037 PI3K/TRF1 inhibitor developed by us significantly
decreased telomere TRF1 foci, induced telomeric DNA damage
and blocked tumor growth as compared to non-treated mice39.
Interestingly, PI3K inhibition enhances DNA damage in breast
cancers that have genetic aberrations in BRCA1 and TP53 by
impairing production of nucleotides needed for DNA synthesis
and repair82, 83. Our work demonstrates a central role of the
PI3K/AKT pathway in regulation of telomere protection, thus
highlighting components of this pathway as novel targets for
telomere-based therapies in cancer and age-related diseases.
Methods
Cell culture assays. Immortalized Mouse embryonic fibroblasts (MEFs) p110α
(lox/lox) or (+/+)75, Trf1+/+ p53−/− or Trf1flox/flox MEFs29, and K-RasΔ/LG12Vgeo
p53−/− tumor-derived cell line CHA-9-3 cell line39, were cultured in DMEM
supplemented with 10% fetal bovine serum (FBS).
For adenoviral infection, cells were infected twice with Adenovirus CMV-CRE-
GFP. Retroviral supernatants were produced in 293T cells (5 × 105 cells per 100
mm diameter dish) transfected with the ecotropic packaging plasmid pCL-Eco and
either pBabe-Cre, pBabe-GFP or eGFP-TRF1 pWzl-Hygro (a gift from T. de Lange,
Addgene plasmid #19834). Two days later, retroviral supernatant (10 ml) were
collected. MEF were seeded the previous day (8 × 105 cells per 100 mm diameter
dish) and received 2 ml of each corresponding retroviral supernatant. This
procedure was repeated three times at 12 h intervals.
Generation of PDXs. Experiments were conducted following the European
Union’s animal care directive (86/609/EEC) and were approved by the Ethical
Committee of Animal Experimentation of the Vall d’Hebron Research Institute
and patient consent. Fresh primary or metastatic human breast tumors were
obtained from patients at time of surgery or biopsy. Fragments of 30–60 mm3 were
immediately implanted into the mammary fat pad (surgery samples) or the lower
flank (metastatic samples) of female athymic NMRI nu/nu mice. Mice were
continuously treated with 17 beta-Estradiol (Sigma-Aldrich) in the drinking water
at 1 μM. Upon growth of the engrafted tumors, the model was perpetuated by serial
transplantation. In each passage, flash frozen and formalin-fixed paraffin embed-
ded samples were taken for genotyping and histological studies. To evaluate the
sensitivity to the drugs one tumor of each PDX model was expanded to 24 recipient
mice. When the tumors reached an average volume of 200 mm3, mice were
separated into two treatment arms: vehicle (0.5% methylcellulose in PBS) or
BYL719 (35 mg/kg QD, 6 days/week). These doses are comparable to 75% of the
human maximum tolerated dose. The treatment was prolonged for 12 days.
In all experiments, mouse weight and tumor dimensions were recorded twice
weekly with a digital caliper starting with the first day of treatment. The tumor
volume was calculated as V= 4π/3(L×l2), “L” being the largest diameter and “l” the
smallest.
Immunofluorescence staining techniques. TRF1 immunofluorescence of TRF1
was performed in lung tumor-derived cell line (CHA9.3) and in MEFs39. A rat
monoclonal antibody against mouse TRF1 developed by the Monoclonal antibody
unit at CNIO was used to detect endogenous TRF1 (1:500). GFP-TRF1 fluores-
cence was directly measured in cells fixed in paraformaldehyde. For quantification
of TRF1 foci intensity, pictures of fixed cells were automatically acquired from each
well by the Opera HCS system (Perkin Elmer). Sixty images of random fields per
well, with a 40× magnification lens, were taken under non-saturating conditions.
At least 1 × 103 cells were analyzed for each well. Briefly, images were segmented
using the DAPI staining to generate masks matching cell nuclei from which-TRF1
foci were analyzed.
Formalin-fixed paraffin-embedded PDXs sections were permeabilized with
0.5% PBS-Triton for 1 h and blocked first with fetal bovine serum for 2 h and then
in 5% BSA for 2 h. Samples were incubated O/N at 4 °C with the primary antibody.
Antibodies used were anti-TRF1 (1:200) (TRF-78, ABCAM, ab10579), anti-RAP1
(1:300) (Bethyl Laboratories, A300-306A), and anti-phospho-histone2 H2AX-
Ser139 (γH2AX) (1:300) (Millipore, 05-636). Slides were further incubated with
488-Alexa or 555-Alexa labeled secondary antibodies. Nuclei were counterstained
in a 4 µg/ml 4′,6-diamino-2-phenylindole (DAPI)/PBS solution before mounting
with Vectashield.
An immune-Fish was performed in formalin-fixed paraffin-embedded PDXs
sections to identify telomeric TRF1 and quantify telomere length. TRF1 foci were
detected by immunofluorescence as described above. Quantitative FISH was
performed as follows: samples were permeabilized for 2 h in PBS-5% Triton,
blocked for 1 h with 5% BSA in PBS, and immunofluorescence with TRF1
homemade rat TRF1 antibody diluted 1:500 was performed. After
immunofluorescence, samples were fixed for 20 min in 4% paraformaldehide in
PBS and followed by Q-FISH. Briefly, samples were washed with PBS and
dehydrate in EtOH 70, 90 and 100%. The samples were then incubated with a
telomeric PNA probe labeled with CY3 (Panagene) in 50% formamide for 30 min,
washed in the presence of 50% formamide and counterstained with DAPI.
Telomeric TRF1 foci were identified by colocalization of CY3 and 488-Alexa
double positive spots. Confocal microscopy was performed at room temperature
with a laser-scanning microscope (TCS SP5; Leica) using a Plan Apo 63Å-1.40 NA
oil immersion objective (HCX; Leica). Maximal projection of Z-stack images
generated using advanced fluorescence software (LAS) was analyzed with the
Definiens XD software package. The DAPI images were used to detect signals
inside the nuclei.
Western blot analysis. Twenty micrograms of nuclear extracts of untreated
control (DMSO) or treated with inhibitors in each cased indicated cells were
resolved in 4–12% SDS/PAGE gels (NuPAGE Invitrogen) and transferred to
nitrocellulose membranes. Blots were incubated with the primary antibodies anti-
TRF1 1:500 (home-made monoclonal Rat, CNIO; TRF-78, ABCAM, ab10579) and
with anti-SMC1 1:2000 (Bethyl Laboratories #A300-055A) as loading control. For
nuclear protein preparation, the Nuclear/Cytosol Fractionation Kit (K266-100,
BioVision) was used according to the manufactures protocol.
For detection of AKT, PRAS40 (T246) and pS6 in CHA9.3 cells, untreated
control (DMSO) or treated with the indicated inhibitors, were lysed in RIPA buffer
supplemented with 100 mM pefablock (Roche Diagnostics) and protease inhibitor
cocktail (Roche Molecular Biochemicals). Proteins were resolved on 10% SDS-
PAGE, and transferred to nitrocellulose membrane (AmershamTM ProtanTM 0.2
µm nNC). Membranes were incubated with antibodies against phospho-AKT
(Ser473), AKT, phospo-S6 (Ser 235/236), and S6Ribosomal from Cell Signaling,
phospo-PRAS40 (Thr246) from BIOSURCE and anti α-tubulin form Sigma,
overnight at 4 °C. After washing, blots were incubated with secondary antibody:
Alexa Fluor 680 goat anti-rabbit IgG (Invitrogen) or anti-mouse IgG DyLight 800
conjugated (Thermo Scientific), and visualized using an Odyssey infrared imaging
system (Li-Cor Biosciences).
Sample preparation for dimerization analysis was performed in the absence of
reducing agents (without dithiothreitol, DTnT, and 2-mercaptoetanol). Proteins
were not pre-heated before gel loading.
Cycloheximide chase experiments were performed in MEFs expressing WT or
mutant (T330A, S344A, T248A, or T330A/S344A) GFP-TRF1. Cells were seeded in
10 cm plates. After 16 h, cells were pre-treated with 100 µg/ml cycloheximide
(Sigma) for 30 min. Cells were then collected at 0, 1, 2, 5, 4, and 5 h. In addition,
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cells were treated with both cycloheximide and the proteasome inhibitor,
Bortezomib (5 µM) for 5 h. Western blot was performed against TRF1 and SMC1
as decribed above.
The uncropped blot scans of this work are shown in Supplementary Figs 4
and 5.
Electrophoretic mobility shift assay. In vitro gel-shift assays were performed
with 1 µg GST-TRF1 wt or mutant (T330A, S344A; T248A) and 32P-labeled ds
(TTAGGG)7 telomeric probe. Briefly, DNA probes were prepared by annealing the
two oligonucleotides, sense (5′-GGGTTAGGGTTAGGGTTAGGGTTAGGGT-
TAGGGTTAGGGTTAGGGCCCCTC-3′) and antisense (5′-GAGGGGCCC-
TAACCCTAACCCTAACCCTAACCCTAACCCTAACCCTAACCC-3′), end-
labeled with [γ-32P]ATP (Amersham Biosciences) and T4-polynucleotide kinase
(New England BioLabs) and purified by free nucleotide removal spin column
(Qiagen). Labeled-DNA probes were incubated with 1 μg of purified TRF1 protein
for 20 min at room temperature in a 30-μl reaction containing 20 mm HEPES-
KOH, pH 7.9, 150 mm KCl, 5% (v/v) glycerol, 4% (w/v) Ficoll, 1 mm EDTA, 0.1
mm MgCl2, 0.5 mm dithiothreitol, and 20 μg of bovine serum albumin, and poly
(dI-dC) (1 μg) as the nonspecific competitor (Amersham Biosciences). For
supershift analysis, recombinant TRF1 was preincubated with anti-TRF1 antibody
(rat homemade) before EMSA. The DNA-protein complexes were resolved on a 5%
non-denaturing polyacrylamide (29:1 acrylamide:bisacrylamide) gel with 0.5× Tris-
borate-EDTA, TBE (Sigma) as running buffer. Gels were dried under a vacuum at
80 °C and auto radiographed.
RNA and qPCR. Total RNA Trf1 expression was quantified by qPCR using the
following primers: TRF1 forward (5′-TCTAAGGATAGGCCAGATGCCA-3′) and
TRF1 reverse (5′-CTGAAATCTGATGGAGCACGTC-3′). GAPDH was used as
the housekeeping gene. We determined the relative expression of Trf1 in each
sample by calculating the 2ΔCT value. For each sample, 2ΔCT was normalized to
the control 2ΔCT mean.
Q-FISH on metaphase spreads. Lung cancer-derived cell line (CHA-9-3) and
immortalized P110αlox/lox MEFS were treated either with 10 µM of ETP-47037,
ETP-47228, or AKTi (MK-2206) for 24 h. Q-FISH in metaphase spreads was
performed as described above, but increasing the concentration of formamide in
both the incubation and the washes to 70%.
In vitro TRF1 phosphorylation. Full-length mouse TRF1 was cloned using the
Gateway™ technology (Thermo Fisher Scientific) into the expression vector
pDEST565, which adds two tags (6xHis and GST) at the N terminus of the encoded
protein. Protein was expressed in Escherichia coli strain BL21(DE3) and purified by
affinity chromatography using a Ni2+ column (HisTrap FF crude, 17-5286-01, GE
Healthcare) in an AKTA Prime system (GE Healthcare), followed by dialysis
against 20 mM phosphate buffer pH 7.5, 200 mM NaCl, 2 mM TCEP.
One μg of purified GST-TRF1 was incubated with 0.2 μg of human GST-AKT1
(1379-0000-2, ProQinase) with or without AKT inhibitor (MK-2206, 25 μM) in
kinase buffer (50 mM Hepes pH 7.9, 100 μM ATP, 10 mM MgCl2, 5 mM DTT)
containing 5 μCi [γ-32-P]ATP in a total volume of 25 μl. The peptide RBER-GSK3
(14-27) (0349-0000-5, ProQinase) (100 ng) was used as positive control. The
reactions were performed at 30 °C for 1 and stopped by addition of Lamely buffer
(6×). Samples were resolved in 4–12% SDS-PAGE gels and subjected to
autoradiography.
Generation of GST-TRF1 and eGFP-TRF1 mutant alleles. For site-directed
mutagenesis, QuickChange lightning multi site-directed mutagenesis (210513,
Agilent Technologies) was used. In brief, PCRs were performed following the
manufacturer’s protocol with either the pDEST565-mTRF1 expression vector or
the eGFP-TRF1 pWzl-Hygro retroviral vector as templates and the following







PCR products were digested with Dpn I restriction enzyme to digest the
parental (non-mutated) DNA for 1 h at 37 °C and then, transformed into XL-10-
Gold® ultracompetent cells. Individual colonies were grown and DNA extracted
with QIAprep Spin Miniprep Kit (27106, QIAGEN). Mutations were confirmed by
sequencing with a specific TRF1 primer 5′-TTCCACTCCCTTTTCCAACACT-3′.
Finally, 50 ng of each mutant DNA was used to transform BL21(DE3). Protein
production and phosphorylation of the respective mutant GST-TRF1 protein were
carried out following the same protocols described above.
Identification of TRF1 phosphopeptides by LC/MS/MS analysis. One μg of
purified GST-TRF1 was incubated with 0.2 μg of human GST-AKT1 (1379-0000-2,
ProQinase) in kinase buffer (50 mM Hepes pH 7.9,100 μM ATP, 10 mM MgCl2, 5
mM DTT) in a total volume of 25 μl for 1 h at 30 °C. Protein samples were diluted
with 9 M urea in 50 mM ammonium bicarbonate (ABC) and subsequently reduced
and carbamidomethylated in 15 mM tris(2-carboxyethyl)phosphine (TCEP) and
30 mM chloroacetamide for 45 min at 25 °C protected from light. After diluting the
urea to 2M with 50 mM ABC, samples were digested overnight with Lys-C (1:50
enzyme/protein w/w), diluted to 1 M urea, and further digested with Trypsin (1:50
enzyme/protein w/w) for 6 h at 37 °C. Resulting peptides were desalted by home-
made C18 Empore tips and analyzed by LC-MS/MS onto a LTQ-OrbitrapVelos
instrument. The raw files were processed using the Proteome Discoverer
1.4.0.1 software. Fragmentation spectra were searched against the mouse Uni-
rprot_KB/Trembl Database (43539 entries), supplemented with a home-made
database comprising the contaminant proteins most commonly found in our
assays, using Sequest as the search engine. The precursor and fragment mass
tolerances were set to 20 p.p.m. and 0.5 Da, respectively, and up to two tryptic
missed cleavages were allowed. Carbamidomethylation of cysteine was considered
as fixed modification, while oxidation of methionine, and phosphorylation of
serine, threonine, and tyrosine were chosen as variable modification for database
searching. The results were filtered to 1% false discovery rate (FDR) using
percolator.
Synthetic protocols for ETP compounds. The HPLC-MS measurements were
performed using a HP 1100 from Agilent Technologies. Method LCM1: Gemini-
NX C18 (100 × 2.9 mm; 5 mm). Solvent A: water with 0.1% formic acid. Solvent B:
acetonitrile with 0.1% formic acid. Gradient: 5% of B to 100% of B within 8 min at
50 °C, DAD. The MS detector was configured with an electrospray ionization
source or API/APCI. Nitrogen was used as the nebulizer gas. [M + 1]+ means the
protonated mass of the compound.
NMR spectra were recorded in a Bruker Advance II 300 spectrometer.
ETP-47228: the compound was synthesized following similar synthetic
procedure reported in WO2010119264 for compound 2-243.
LCMS1: retention time: 2.98 min, [M + 1]+= 555.1.
1H NMR (300MHz, DMSO) δ 8.91 (s, 1H), 8.88 (s, 1H), 8.18 (s, 1H), 8.02 (d, J
= 8.7 Hz, 2H), 7.54 (d, J = 8.7 Hz, 4H), 7.52 (d, J= 8.7 Hz, 2H), 7.35 (s, 1H), 7.33
(d, 2H), 4.27 (m, 4H), 3.78 (m, 4H), 3.49 (wide s, 4H), 2.50 (s, 3H), 2.31 (m, 4H),
2.19 (s, 3H).
ETP-50952: the compound was synthesized following the similar synthetic
procedure used for synthesis of ETP-47228.
LCMS1: retention time: 3.26 min, [M + 1]+= 553.1.
1H NMR (300MHz, DMSO) δ 8.93 (s, 1H), 8.88 (s, 1H), 8.10 (s, 1H), 8.01 (d, J
= 8.7 Hz, 2H), 7.55 (d, J = 8.7 Hz, 2H), 7.52 (d, J= 8.7 Hz, 2H), 7.34 (d, J= 8.4 Hz,
2H), 7.33 (s, 1H), 4.28 (m, 4H), 3.49 (m, 4H), 2.50 (s, 3H under DMSO-d6 signal),
2.31 (m, 4H), 2.20 (s, 3H), 1.67 (m, 6H).
ETP-47037: synthetic procedure and analytical data are reported in
WO2011089400 (compound 3–10 of the patent).
ETP-51259: the compound was synthesized following the similar synthetic
procedure used for synthesis of ETP-47037.
LCMS1: retention time: 1.94 min, [M + 1]+= 472.6.
1H NMR (300MHz, DMSO) δ 8.85 (s, 2H), 8.58 (s, 1H), 6.82 (s, 3H), 3.77 (m,
6H), 3.12 (m, 4H), 2.87 (s, 3H), 2. 55 (m, 4H), 1.67 (m, 6H).
Synthesis of ETP-46992. The synthesis of ETP-46992 is described in ref. 66.
Commercial inhibitors used in the study. The commercially available PI3K/
mTOR and AKT inhibitors, GDC-0941, BKM-120, BYL-719, TGX-221, BEZ-235,
GSK-2126458, and MK-2206, described in the manuscript were purchased from
Selleckchem (www.selleckchem.com). The inhibitors were tested at 10 μM except
GSK-2126458 that was used at 1.0 μM.
PI3K alpha biochemical assay. The kinase activity was measured by using the
commercial ADP HunterTM Plus assay available from DiscoveRx (#33-016), which
is a homogeneous assay to measure the accumulation of ADP, a universal product
of kinase activity. The enzyme, PI3K (p110α) was purchased from Cama Bios-
ciences (#07CBS-0402A). The assay was performed following the manufacturer
recommendations. To calculate the IC50 of the selected compounds, serial 1:5
dilutions were used in a concentration range from 128 pM to 50 μM fluorescence
counts were read in a Victor instrument (Perkin Elmer) with the recommended
settings (544 and 580 nm as excitation and emission wavelengths, respectively).
Values were normalized against the control activity included for the enzyme (Le.,
100 % PI3 kinase activity, without compound). These values were plotted against
the inhibitor concentration and were fit to a sigmoid dose-response curve by using
Activity base software from IDBS.
PI3K isoforms biochemical assay. PI3Kα (p110α/p85α), PI3K-δ (p110δ/p85α),
and PI3K-γ (p110γ) were purchased from Invitrogen (PV4789, PV 5274, and
PV4787, respectively). PI3K-β (p110β/p85α) was obtained from Millipore (#14-
603). The kinase activity was measured with the commercial PI3-kinase (human)
HTRF™ assay available from Millipore (#33-017), following the manufacturer
recommendations. The final enzyme concentration in the assay were 100 pM for
PI3K-α and PI3K-δ, 500 pM for PI3K-β, and 4 nM for PI3K-γ. To calculate the
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IC50 of the selected compounds, serial 1:5 dilutions were used in a concentration
range from 12 pM to 25 μM. The enzyme was preincubated with the inhibitor and
with 10 μM of PIP2 for 5 min. The enzymatic reaction was started by addition of
ATP at 50 times the Km. The incubation was kept at 37 °C for 60 min. Stop
solution and detection mix were added sequentially to the wells and plates were
incubated 3 h in the dark at 25 °C. HTRF counts were measured in an EnVision
reader (Perkin Elmer) using the recommended settings. Values were normalized
against the control activity included for the enzyme (100% PI3 kinase activity,
without compound). These values were plotted against the inhibitor concentration
and were fit to a sigmoid dose-response curve by using Activity base software from
IDBS.
mTOR biochemical assay. mTOR biochemical assay was performed with a
LanthaScreen™ kinase activity assay form invitrogen. The kinase mTOR (FRAP1;
ThermoFisher, PV4753), a GFP-labeled substrate (GFP-4E BP1, ThermoFisher,
PV4759), and ATP were allowed to react. Then EDTA was added to stop the
reaction and terbium-labeled antibody, Tb-anti-p4EBP1 (phosphorthreonine 46)
(ThermoFisher, PV4758) to detect phosphorylated product. in a LanthaScreen™
kinase reaction, the antibody associates with the phosphorylated GFP-labeled
substrate resulting in an increased TR-FRET value. The TR-FRET value is a
dimensionless number that is calculated as the ratio of the acceptor (GFP) signal to
the donor (terbium) signal. The amount of antibody that is bound to the tracer is
directly proportional to the amount of phosphorylated substrate, so that kinase
activity can be measured by an increase in the TR-FRET value. To calculate the
IC50 of the selected compounds, serial 1:3 dilutions were used in a concentration
range from 1.49 nM to 10 μM. Fluorescence counts were read in an Victor reader
(Perkin Elmer) with the recommended settings (495 and 520 nm as emission
wavelengths for Terbium and GFP, respectively). Values were normalized against
the control activity included for the enzyme (100% mTOR activity, without
compound). These values were plotted against the inhibitor concentration and
were fit to a sigmoid dose-response curve by using Activity base software from
IDBS.
Data availability. The authors declare that the data supporting the findings of this
study are available from the authors.
Received: 12 April 2017 Accepted: 11 September 2017
References
1. Blackburn, E. H. Structure and function of telomeres. Nature 350, 569–573
(1991).
2. Greider, C. W. & Blackburn, E. H. Identification of a specific telomere terminal
transferase activity in Tetrahymena extracts. Cell 43, 405–413 (1985).
3. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell
144, 646–674 (2011).
4. Baerlocher, G. M. et al. Telomerase inhibitor imetelstat in patients with
essential thrombocythemia. N. Engl. J. Med. 373, 920–928 (2015).
5. Jafri, M. A., Ansari, S. A., Alqahtani, M. H. & Shay, J. W. Roles of telomeres and
telomerase in cancer, and advances in telomerase-targeted therapies. Genome
Med. 8, 69 (2016).
6. Tefferi, A. et al. A pilot study of the telomerase inhibitor imetelstat for
myelofibrosis. N. Engl. J. Med. 373, 908–919 (2015).
7. Samper, E., Flores, J. M. & Blasco, M. A. Restoration of telomerase activity
rescues chromosomal instability and premature aging in Terc−/− mice with
short telomeres. EMBO Rep. 2, 800–807 (2001).
8. Hemann, M. T., Strong, M. A., Hao, L. Y. & Greider, C. W. The shortest
telomere, not average telomere length, is critical for cell viability and
chromosome stability. Cell 107, 67–77 (2001).
9. Gonzalez-Suarez, E., Samper, E., Flores, J. M. & Blasco, M. A. Telomerase-
deficient mice with short telomeres are resistant to skin tumorigenesis. Nat.
Genet. 26, 114–117 (2000).
10. Seger, Y. R. et al. Transformation of normal human cells in the absence of
telomerase activation. Cancer Cell 2, 401–413 (2002).
11. Blasco, M. A. Telomere length, stem cells and aging. Nat. Chem. Biol. 3,
640–649 (2007).
12. de Lange, T. Shelterin: the protein complex that shapes and safeguards human
telomeres. Genes Dev. 19, 2100–2110 (2005).
13. Zhong, Z., Shiue, L., Kaplan, S. & de Lange, T. A mammalian factor that binds
telomeric TTAGGG repeats in vitro. Mol. Cell. Biol. 12, 4834–4843 (1992).
14. Bianchi, A., Smith, S., Chong, L., Elias, P. & de Lange, T. TRF1 is a dimer and
bends telomeric DNA. EMBO J. 16, 1785–1794 (1997).
15. Boskovic, J. et al. Molecular architecture of full length TRF1 favors its
interaction with DNA. J. Biol. Chem. 291, 21829–21835 (2016).
16. Chang, W., Dynek, J. N. & Smith, S. TRF1 is degraded by ubiquitin-mediated
proteolysis after release from telomeres. Genes Dev. 17, 1328–1333 (2003).
17. Kaminker, P. G. et al. TANK2, a new TRF1-associated poly(ADP-ribose)
polymerase, causes rapid induction of cell death upon overexpression. J. Biol.
Chem. 276, 35891–35899 (2001).
18. Cook, B. D., Dynek, J. N., Chang, W., Shostak, G. & Smith, S. Role for the
related poly(ADP-Ribose) polymerases tankyrase 1 and 2 at human telomeres.
Mol. Cell. Biol. 22, 332–342 (2002).
19. Smith, S., Giriat, I., Schmitt, A. & de Lange, T. Tankyrase, a poly(ADP-ribose)
polymerase at human telomeres. Science 282, 1484–1487 (1998).
20. Lee, T. H., Perrem, K., Harper, J. W., Lu, K. P. & Zhou, X. Z. The F-box protein
FBX4 targets PIN2/TRF1 for ubiquitin-mediated degradation and regulates
telomere maintenance. J. Biol. Chem. 281, 759–768 (2006).
21. Wu, Z. Q., Yang, X., Weber, G. & Liu, X. Plk1 phosphorylation of TRF1 is
essential for its binding to telomeres. J. Biol. Chem. 283, 25503–25513 (2008).
22. McKerlie, M. & Zhu, X. D. Cyclin B-dependent kinase 1 regulates human TRF1
to modulate the resolution of sister telomeres. Nat. Commun. 2, 371 (2011).
23. Kim, M. K. et al. Regulation of telomeric repeat binding factor 1 binding to
telomeres by casein kinase 2-mediated phosphorylation. J. Biol. Chem. 283,
14144–14152 (2008).
24. Chen, Y. C., Teng, S. C. & Wu, K. J. Phosphorylation of telomeric repeat
binding factor 1 (TRF1) by Akt causes telomere shortening. Cancer Invest. 27,
24–28 (2009).
25. Tan, R. et al. Nek7 protects telomeres from oxidative DNA damage by
phosphorylation and stabilization of TRF1. Mol. Cell 65, 818–831e5 (2017).
26. Schneider, R. P. et al. TRF1 is a stem cell marker and is essential for the
generation of induced pluripotent stem cells. Nat. Commun. 4, 1946 (2013).
27. Karlseder, J. et al. Targeted deletion reveals an essential function for the
telomere length regulator Trf1. Mol. Cell. Biol. 23, 6533–6541 (2003).
28. Sfeir, A. et al. Mammalian telomeres resemble fragile sites and require TRF1 for
efficient replication. Cell 138, 90–103 (2009).
29. Martinez, P. et al. Increased telomere fragility and fusions resulting from TRF1
deficiency lead to degenerative pathologies and increased cancer in mice. Genes
Dev. 23, 2060–2075 (2009).
30. Beier, F., Foronda, M., Martinez, P. & Blasco, M. A. Conditional TRF1
knockout in the hematopoietic compartment leads to bone marrow failure and
recapitulates clinical features of dyskeratosis congenita. Blood 120, 2990–3000
(2012).
31. Povedano, J. M., Martinez, P., Flores, J. M., Mulero, F. & Blasco, M. A. Mice
with pulmonary fibrosis driven by telomere dysfunction. Cell Rep. 12, 286–299
(2015).
32. Bainbridge, M. N. et al. Germline mutations in shelterin complex genes are
associated with familial glioma. J. Natl. Cancer Inst. 107, 384 (2014).
33. Calvete, O. et al. A mutation in the POT1 gene is responsible for cardiac
angiosarcoma in TP53-negative Li-Fraumeni-like families. Nat. Commun. 6,
8383 (2015).
34. Newey, P. J. et al. Whole-exome sequencing studies of nonhereditary (sporadic)
parathyroid adenomas. J. Clin. Endocrinol. Metab. 97, E1995–E2005 (2012).
35. Ramsay, A. J. et al. POT1 mutations cause telomere dysfunction in chronic
lymphocytic leukemia. Nat. Genet. 45, 526–530 (2013).
36. Robles-Espinoza, C. D. et al. POT1 loss-of-function variants predispose to
familial melanoma. Nat. Genet. 46, 478–481 (2014).
37. Shi, J. et al. Rare missense variants in POT1 predispose to familial cutaneous
malignant melanoma. Nat. Genet. 46, 482–486 (2014).
38. Zhang, J. et al. The genomic landscape of mantle cell lymphoma is related to the
epigenetically determined chromatin state of normal B cells. Blood 123,
2988–2996 (2014).
39. Garcia-Beccaria, M. et al. Therapeutic inhibition of TRF1 impairs the growth of
p53-deficient K-RasG12V-induced lung cancer by induction of telomeric DNA
damage. EMBO Mol. Med. 7, 930–949 (2015).
40. Engelman, J. A., Luo, J. & Cantley, L. C. The evolution of phosphatidylinositol
3-kinases as regulators of growth and metabolism. Nat. Rev. Genet. 7, 606–619
(2006).
41. Vanhaesebroeck, B., Stephens, L. & Hawkins, P. PI3K signalling: the path to
discovery and understanding. Nat. Rev. Mol. Cell. Biol. 13, 195–203 (2012).
42. Osaki, M., Oshimura, M. & Ito, H. PI3K-Akt pathway: its functions and
alterations in human cancer. Apoptosis 9, 667–676 (2004).
43. Weigelt, B. & Downward, J. Genomic determinants of PI3K pathway inhibitor
response in cancer. Front. Oncol. 2, 109 (2012).
44. Massacesi, C. et al. PI3K inhibitors as new cancer therapeutics: implications for
clinical trial design. Onco Targets Ther. 9, 203–210 (2016).
45. Hennessy, B. T., Smith, D. L., Ram, P. T., Lu, Y. & Mills, G. B. Exploiting the
PI3K/AKT pathway for cancer drug discovery. Nat. Rev. Drug Discov. 4,
988–1004 (2005).
46. Yuan, T. L. & Cantley, L. C. PI3K pathway alterations in cancer: variations on a
theme. Oncogene 27, 5497–5510 (2008).
47. Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57–70
(2000).
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-01329-2
16 NATURE COMMUNICATIONS | 8:  1278 |DOI: 10.1038/s41467-017-01329-2 |www.nature.com/naturecommunications
48. Kenyon, C. The plasticity of aging: insights from long-lived mutants. Cell 120,
449–460 (2005).
49. Lopez-Otin, C., Blasco, M. A., Partridge, L., Serrano, M. & Kroemer, G. The
hallmarks of aging. Cell 153, 1194–1217 (2013).
50. Bjedov, I. et al. Mechanisms of life span extension by rapamycin in the fruit fly
Drosophila melanogaster. Cell Metab. 11, 35–46 (2010).
51. Harrison, D. E. et al. Rapamycin fed late in life extends lifespan in genetically
heterogeneous mice. Nature 460, 392–395 (2009).
52. Partridge, L. Some highlights of research on aging with invertebrates, 2010.
Aging Cell 10, 5–9 (2010).
53. Piper, M. D., Selman, C., McElwee, J. J. & Partridge, L. Separating cause from
effect: how does insulin/IGF signalling control lifespan in worms, flies and
mice? J. Intern. Med. 263, 179–191 (2008).
54. Selman, C. et al. Ribosomal protein S6 kinase 1 signaling regulates mammalian
life span. Science 326, 140–144 (2009).
55. Takahashi, K., Murakami, M. & Yamanaka, S. Role of the phosphoinositide 3-
kinase pathway in mouse embryonic stem (ES) cells. Biochem. Soc. Trans. 33,
1522–1525 (2005).
56. Hossini, A. M. et al. PI3K/AKT signaling pathway is essential for survival of
induced pluripotent stem cells. PLoS ONE 11, e0154770 (2016).
57. Silva, J. et al. Promotion of reprogramming to ground state pluripotency by
signal inhibition. PLoS Biol. 6, e253 (2008).
58. Beurel, E., Grieco, S. F. & Jope, R. S. Glycogen synthase kinase-3 (GSK3):
regulation, actions, and diseases. Pharmacol. Ther. 148, 114–131 (2015).
59. Pastor-Fernandez, J. et al. Inhibitors of PI3 kinase (WO2011089400, 2011).
60. Pastor-Fernandez, J., Martinez-Gonzalez, S. & Oyarzabal-Santamarina, J.
Imidazopyrazines for use as kinase inhibitors (WO-2010119264, 2010).
61. Burgering, B. M. & Coffer, P. J. Protein kinase B (c-Akt) in
phosphatidylinositol-3-OH kinase signal transduction. Nature 376, 599–602
(1995).
62. Franke, T. F. et al. The protein kinase encoded by the Akt proto-oncogene is a
target of the PDGF-activated phosphatidylinositol 3-kinase. Cell 81, 727–736
(1995).
63. Nicholson, K. M. & Anderson, N. G. The protein kinase B/Akt signalling
pathway in human malignancy. Cell. Signal. 14, 381–395 (2002).
64. Flotow, H. & Thomas, G. Substrate recognition determinants of the mitogen-
activated 70K S6 kinase from rat liver. J. Biol. Chem. 267, 3074–3078 (1992).
65. Kovacina, K. S. et al. Identification of a proline-rich Akt substrate as a 14-3-3
binding partner. J. Biol. Chem. 278, 10189–10194 (2003).
66. Martinez Gonzalez, S. et al. Rapid identification of ETP-46992, orally
bioavailable PI3K inhibitor, selective versus mTOR. Bioorg. Med. Chem. Lett.
22, 5208–5214 (2012).
67. Folkes, A. J. et al. The identification of 2-(1H-indazol-4-yl)-6-(4-
methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-t hieno[3,2-d]
pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of
class I PI3 kinase for the treatment of cancer. J. Med. Chem. 51, 5522–5532
(2008).
68. Maira, S. M. et al. Identification and characterization of NVP-BKM120, an
orally available pan-class I PI3-kinase inhibitor. Mol. Cancer Ther. 11, 317–328
(2012).
69. Furet, P. et al. Discovery of NVP-BYL719 a potent and selective
phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation.
Bioorg. Med. Chem. Lett. 23, 3741–3748 (2013).
70. Jackson, S. P. et al. PI 3-kinase p110beta: a new target for antithrombotic
therapy. Nat. Med. 11, 507–514 (2005).
71. Maira, S. M. et al. Identification and characterization of NVP-BEZ235, a new
orally available dual phosphatidylinositol 3-kinase/mammalian target of
rapamycin inhibitor with potent in vivo antitumor activity. Mol. Cancer Ther.
7, 1851–1863 (2008).
72. Yan, L. MK-2206: a potent oral allosteric AKT inhibitor. 100th Annual Meeting
of the American Association for Cancer Research Abstract DDT01–1 (2009).
73. Knight, S. D. et al. Discovery of GSK2126458, a highly potent inhibitor of PI3K
and the mammalian target of rapamycin. ACS Med. Chem. Lett. 1, 39–43
(2010).
74. Fritsch, C. et al. Characterization of the novel and specific PI3Kalpha inhibitor
NVP-BYL719 and development of the patient stratification strategy for clinical
trials. Mol. Cancer Ther. 13, 1117–1129 (2014).
75. Zhao, J. J. et al. The p110alpha isoform of PI3K is essential for proper growth
factor signaling and oncogenic transformation. Proc. Natl Acad. Sci. USA 103,
16296–16300 (2006).
76. Donigian, J. R. & de Lange, T. The role of the poly(ADP-ribose) polymerase
tankyrase1 in telomere length control by the TRF1 component of the shelterin
complex. J. Biol. Chem. 282, 22662–22667 (2007).
77. Broccoli, D., Smogorzewska, A., Chong, L. & de Lange, T. Human telomeres
contain two distinct Myb-related proteins, TRF1 and TRF2. Nat. Genet. 17,
231–235 (1997).
78. Serra, V. et al. PI3K inhibition results in enhanced HER signaling and acquired
ERK dependency in HER2-overexpressing breast cancer. Oncogene 30,
2547–2557 (2011).
79. van Steensel, B. & de Lange, T. Control of telomere length by the human
telomeric protein TRF1. Nature 385, 740–743 (1997).
80. Munoz, P. et al. TRF1 controls telomere length and mitotic fidelity in epithelial
homeostasis. Mol. Cell. Biol. 29, 1608–1625 (2009).
81. Ho, A. et al. TRF1 phosphorylation on T271 modulates telomerase-dependent
telomere length maintenance as well as the formation of ALT-associated PML
bodies. Sci. Rep. 6, 36913 (2016).
82. Juvekar, A. et al. Phosphoinositide 3-kinase inhibitors induce DNA damage through
nucleoside depletion. Proc. Natl Acad. Sci. USA 113, E4338–E4347 (2016).
83. Juvekar, A. et al. Combining a PI3K inhibitor with a PARP inhibitor provides
an effective therapy for BRCA1-related breast cancer. Cancer Discov. 2,
1048–1063 (2012).
Acknowledgements
We are indebted to D. Megias for microscopy analysis, to D. Calvo for protein pur-
ification as well as to J. Muñoz and F. García for LC/MS/MS analysis. The research was
funded by project SAF2013-45111-R of Societal Changes Program of the Spanish Min-
istry of Economics and Competitiveness (MINECO) co-financed through the European
Fund of Regional Development (FEDER), Fundación Botín, Banco Santander (Santander
Universities Global Division) and Worldwide Cancer Research (WCR 16-1177).
Author contributions
M.A.B., P.M. and M.M.-P. performed experiments and wrote the manuscript. C.B.,
E.G.-C., A.B.G. and J.P. performed the chemical studies of the PI3K/AKT inhibitors.
J.M.-T. performed TRF1 protein purification. M.P., J.C. and V.S. provided PDX samples.
Additional information
Supplementary Information accompanies this paper at doi:10.1038/s41467-017-01329-2.
Competing interests: The authors declare no competing financial interests.
Reprints and permission information is available online at http://npg.nature.com/
reprintsandpermissions/
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this license, visit http://creativecommons.org/
licenses/by/4.0/.
© The Author(s) 2017
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-01329-2 ARTICLE
NATURE COMMUNICATIONS |8:  1278 |DOI: 10.1038/s41467-017-01329-2 |www.nature.com/naturecommunications 17
